Quantum Genomics

Developing first in class cardiovascular drugs

European Smallcap Event - 27 & 28 avril 2015

ALQGC LISTED ALTERNEXT

Disclaimer

This document has been prepared by Quantum Genomics ("the Company") solely for use at this presentation. By receiving this presentation and taking part to this meeting you acknowledge that you have read the following restrictions.

This document is confidential and is not to be reproduced by any person, nor to be distributed. Certain information contained in this presentation includes forward-looking statements. Forward-looking statements are not guarantees of future performance of Quantum Genomics and its actual financial condition, actual results of operations and cash flows and the development of the industry in which it operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if Quantum Genomics's financial condition, results of operations and cash flows and the development of the industry in which Quantum Genomics operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. Quantum Genomics does not undertake, nor does it have any obligation, to provide updates or to revise any forward-looking statements to reflect events that occur or circumstances that arise after the date of this presentation. Quantum Genomics takes no responsibility for the use of this information by any person.

The information contained in this presentation has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The information set out herein is subject to updating, completion, revision, verification and amendment and such information may change materially. Quantum Genomics is under no obligation to keep current the information contained in this presentation and any opinion expressed in them is subject to change without notice. Quantum Genomics shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its contents or otherwise arising in connection with this document. It is not the purpose of this presentation to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of Quantum Genomics's financial or commercial position or prospects. A detailed description of the business and financial conditions of Quantum Genomics and a section "Facteurs de risques" ("risk factors") are included in the Offering Circular. Copies of the Offering Circular are available on the web site of the AMF (www.amf-france.org) and of Quantum Genomics (www.quantum-genomics.com).

This document does not constitute an offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any shares of Quantum Genomics in the United States or any other jurisdiction and nor any part of it shall form the basis of, or be relied upon in connection with, any contract, commitment or investment decision in relation thereto.

This presentation is directed only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Articles 49(2)(a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc") of the Financial Promotion Order, (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any shares may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This presentation is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This presentation is solely for your information on a confidential basis and may not be reproduced, redistributed or published (whether internally or externally to your company), directly or indirectly, in whole or in part, to any other person. Neither this document nor any copy of it may be taken, transmitted into or distributed in the United States of America, Canada, Australia, Japan or to any resident of these countries. The distribution of this document in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities law.

Copies of the Document de Base filed with the AMF on January 26, 2015 under the number I. 15-036 may be obtained free of charge and upon request from Quantum Genomics, 2 -12 Chemin des Femmes, Bâtiment l'Odyssée, 91300 Massy, France - and from the internet websites of Quantum Genomics (www.quantum-genomics.com) and the AMF (www.amf-france.org).

Quantum Genomics draws the public's attention to chapter 4, "Risk factors", of the Document de Base registered with the AMF.

Do you know that ?

1/3

Of adults and more, depending on countries has high blood pressure. With the proportion going up to one in two for people aged 50 and above[1]

9.4 million

Deaths worlwide every year due to complications of high blood pressure[1]

1/3

Are dying due to cardiovascular diseases. 1st cause of death with 17 million deaths in the world each year[1]

"Hyper-pressure contributes to nearly 9.4 million deaths due to heart disease and stroke every year and, together, these two diseases are the number one cause of death worldwide. And, hyper-pressure also increases the risk of kidney failure, blindness and several other conditions. It often occurs together with other risk factors like obesity, diabetes and high cholesterol – increasing the health risk even further."

WHO Chief Dr Margaret Chan – World Health Day April 07, 2013

$ 40 billion

Global anti-hypertensive drugs market in 2013[2]

$ 39 billion

Global heart failure drugs market in 2015[3]

Sources : (1) WHO (World Health Organization) - A global brief on hypertension, Silent killer, global public health crisis (2013),
(2) the pharmaletter (June 2014),
(3) Heidenreich et al, Circulation Heart Failure (2013)

Hypertension : the « silent killer » leading to global public health crisis



> 50% of treated patients still have high blood pressure

Using : Diuretics, beta-blockers, ACEi, ARBs, Calcium Channel blockers

x2 the risk of death from stroke or heart attack

Increase of 20/10 mmHg is associated to this risk



A strong need to develop new classes of drugs to improve hypertension control

Sources: Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study - 2011

Table of contents


1 BAPAI : novel therapeutic class


2 Robust pipeline of new drug candidates


3 Efficient organization and strong assets


4 A strategy focused on rapid value creation


5 Terms of the operation

Quantum Genomics

1 BAPAI : novel therapeutic class

BAPAI : a new therapeutic approach to cure hypertension and associated cardiovascular diseases

Brain Aminopeptidase A Inhibitors ***(BAPAIs)***

- Hypertension
- Heart failure
- Other diseases

Quantum Genomics, the « *BAPAI company* », is developing first in class treatment targeting a new pharmacological pathway in the brain

Benefiting from more than 20 years of the highest standard academic research in Europe

Catherine Llorens-Cortes,

PhD in Neurobiology, Director of the Central Neuropeptides and cardio-vascular hydro-regulation research team – College de France CIRB-CNRS UMR U1050 7241/INSERM

Inserm

Collège de France 1530

Prix Galien de la recherche pharmaceutique

2014
Category
« Research team »

A triple mechanism of action with a single drug

Inhibition of Aminopeptidase A



- ↘ Vasopressin release
- ↘ Sympathetic nerve activity
- ↗ Baroreflex

- Increase of the diuresis (urinary elimination)
- Lowering vascular resistance
- Controlling heart rate

BAPAIs are innovative drugs that target a new central pharmacological pathway leading to both antihypertensive effects and cardioprotection

The first targeted population : LRHV
Low Renin High Vasopressin patients

- **Mostly uncontrolled or poorly controlled : LRHV patients**

- LRHV is overexpressed in elderly, Asian, Afro-American and Hispanic populations
- ACEs and ARBs drugs are not a therapeutic option for those patients

Quantum Genomics

2 Robust pipeline of new drug candidates

A robust pipeline of new drug candidates



Typically, identification and preclinical phases last 2-3 years, a phase I 1-2 years, a phase IIa 1-2 years , a Phase IIb 1-2 years, a phase III 2-3 years and new drug approval and commercialization 2-3 years.

QGC001, a first in class drug candidate to treat hypertension

- **Mechanism of action:** a brain penetrating prodrug
  - QGC001 is able to release in the brain the specific and selective APA inhibitor EC33 which blocks the production of brain angiotensin III

- **Success of preclinical studies**

Stability profile	Chemical stability and properties compatible with the development of a solid dosage form
Pharmacokinetics	High bioavailability in dogs
Toxicity	No toxiciy observed in rats and dogs up to 1,000 mg/kg, no cardiac toxicity, no genotoxicity, no hepatotoxicity
Efficacy	Efficacy demonstrated in hypertensive rats (SHR & DOCA Salt rats) at 15 mg/kg per os.

Approval for initiating the first in human Phase I clinical study

QGC001, results of phase I trials

Target discovery | Identification of active compounds | Preclinical studies | Clinical studies Phase I | Clinical studies Phase II

QGC001

First-in-class

Stand alone treatment of Hypertension

Phase Ia • 2012

Randomized, double blind, placebo controlled study of single ascending doses in 80 healthy volunteers

› **Positive : overall safety and tolerability of QGC001 up to 2g**

Phase Ib • 2013

Randomized, double blind, placebo controlled study of multiple ascending doses in 44 healthy volunteers

› **Positive : overall safety and tolerability of QGC001 up to 750mg twice a day and no food interaction**

Phase IIa • Q1 2015

Initiation of a phase IIa in hypertensive patients

› **Michel Azizi, MD,**

Medical Doctor, University Professor – Hospital Practitioner Director of CIC 9201 (Cardiovascular, renal, endocrine pathology and physiology)

HEGP
Hôpital Européen Georges Pompidou

QGC001, design of the Phase IIa Clinical Trial

- **Example for one patient :**



- **4 Centers in France all labelled as "Centers of Excellence" by the European Society of Hypertension**
  - Hôpital Européen Georges Pompidou – Paris – Pr. Michel Azizi
  - Hôpital de la Croix Rousse – Lyon – Pr. Pierre Lantelme
  - Hôpital Cardiologique, CHRU – Lille – Pr. Claire Mounier-Vehier
  - Hôpital Arthur Gardiner – Dinard – Pr. Thierry Denolle

Balanced pipeline creates long term value

QGC011

Combo BAPAI / IEC

Treatment of hypertension in combination with other antihypertensives/ combination therapy for reduced dosing and reduction of side effects



- **An alternative product to currently marketed antihypertensive drugs**
  - Therapeutic solution for patients poorly or not controlled by existing treatments
  - Synergistic action that allows to dosage reduction and minimized side effects

- **Preclinical results demonstrating high interest in combination with the Angiotensin Converting Enzyme inhibitor, Enalapril (Renitec/Vasotec)**

Synergy of action should improve the control of BP in hypertensive patients



Balanced pipeline creates long term value

QGC006

Best-in-class

Optimized treatment of hypertension as monotherapy / 10x AminopeptidaseA inhibition vs. QGC-001



- **Extended research program to identify new BAPAI's**
  - Improved inhibition, better selectivity versus other enzymes or other receptors
- **2nd generation drug**
  - 10 times more potent inhibitor of Aminopeptidase A compared to QGC001

Reinforcement of the patents' portfolio of Quantum Genomics PLUS increase the lifetime of BAPAI's drugs

QGC101, to prevent and treat congestive heart failure

QGC101

First-in-class

Prevention and treatment of congestive heart failure



- **APA plays a major role in several diseases**
  - The potential of BAPAI has been demonstrated in the prevention and treatment of congestive heart failure in a first study in rodents
- **Two preclinical studies for QGC101**
  - Proof of efficiency in a rodent model and in a dog model

Widening the potential of *BAPAI* towards other diseases

Widening towards animal health market

Signature in January 2014 of a collaborative agreement, with license option, with a major company in the domain of animal health to treat heart failure in dogs

Anticipated milestones

	2015	2016
QGC001	Optimization of the galenic and the pharmaceutical form ✓ **Results of 3 month repeated doses: toxicity studies rats and dogs** ✓ **Patients enrollment of 50% and toxicity results**	✓ **patient enrollment : 100%** ✓ **Results clinical trials phase IIa by end of June** File at CTA to launch of pivotal phase II trial
QGC011	✓ **Results of repeated doses in hypertensive rats** ✓ **Results of PK & Tox repeated doses in rats**	✓ **Results of PK & Tox repeated doses in dogs**
QGC006	✓ **Results of unique dose in hypertensive rats**	Start Pilot production Start regulatory toxicity studies
QGC101	Preliminary results on post infarction heart failure (rats 28 days) ✓ **Results of repeated doses in congestive heart failure (dog models) by end of June** ✓ **Potential licence agreement in animal health by end of December**	✓ **Results on post infarction heart failure (rats – 3 months)**

Quantum Genomics



3 Efficient organization and strong assets

Management team

Lionel Ségard - President & CEO

Former CEO of'Inserm-Transfert, subsidiary of INSERM (French National Institute for Health and Medical Research)
Founder and former president of Inserm Transfert Initiative (seed fund dedicated to healthcare young innovative companies)
Founder of the Strategic Council for Innovation (secretary general from 2003 to 2005), The Council's goal is to boost French efforts in the field of research and high technologies and included key figures from France's science, industry and financial community
Biochemist by training (University of South Paris - Orsay).



Jean-Philippe Milon, PhD - Chief Operating Officer

Several management positions at Bayer HealthCare, then member of the Worldwide Executive Committee as head of WW Business Development, Licensing, Mergers & Acquisitions
Previously head of the cardiovascular business at Sandoz
More than 25 years of experience in Healthcare mainly in the Pharmaceutical Industry.

Marc Karako - Chief Financial Officer

Previously Executive Vice President & Chief Financial Officer of Carlson Wagonlit Travel.
Former Chief Financial and Legal Officer of Vallourec. Former Vice President Finance at Thomson Multimedia.
10 years at IBM in various financial management positions.
Master of engineering (Ecole des Ponts ParisTech) and MBA from the University of Chicago.



Fabrice Balavoine - Vice President Research & Development

15 years of experience in Drug Discovery and Drug Development.
Participated in the development of several drug candidates (new chemical entities, peptides and recombinant proteins) that reached clinical stages in different therapeutic areas. Ph.D. in Organic Chemistry from the University Paris-Sud, master of science from Ecole Supérieure de Physique et de Chimie Industrielle of Paris (ESPCI) and Executive MBA from the ESSEC & Mannheim Business School.

Olivier Madonna - Chief Medical Officer

In depth knowledge of international R&D processes within pharmaceutical , biotech and medical device industries.
Previous experience as Head of cardiovascular medical depatrments with MSD and J&J.
MD Cardiologist , Nephrologist, Specialist in Internal Medicine.

Scientific Advisory Board

Pierre Corvol, MD, Chairman

Professor Emeritus at Collège de France • Honorary President of Collège de France
Member of the Academy of Sciences • Member of the Academy of Medicine
Member of the American Academy of Arts and Sciences



Professor John C.Burnett Jr

Marriott Family Cardiovascular Research Professor, Mayo Clinic
Member, American Society for Clinical Investigation
Member, Association of American Physicians

Professor Mark Caulfield

Co-director of William Harvey Research Institute, Barts and The London School of Medicine and Dentistry,
Queen Mary University of London (UK) • Director of the NIHR Biomedical Research Unit in Cardiovascular Disease at Barts (UK)
Member of the Academy of Medical Sciences in the UK



Professor Alexandre Persu

Head of the Hypertension Clinic, Cardiology Department, Cliniques Universitaires Saint-Luc,
Catholic University of Louvain, Brussels, Belgium
Member of the International and European Society of Hypertension

Strong and broad Intellectual Property

	Patent family 1 (granted)	Patent family 2 (granted)	Patent family 3 (granted)	Patent family 4 (filed)	Patent family 5 (filed)	Patent family 6 (filed)
Filed by	Inserm, cnrs (exclusive WW license)	Inserm, cnrs, Université Paris Descartes (exclusive WW license)	Inserm, cnrs, Université Paris Descartes (exclusive WW license)	Quantum Genomics	Inserm, Quantum Genomics	Quantum Genomics
Area of invention	Concept of BAPAI to treat hypertension (active ingredient patent)	QGC001 for the treatment of hypertension and related diseases	QGC006 for the treatment of hypertension and related diseases	Manufacturing process of QGC001	QGC011 for the treatment of hypertension and related diseases	QGC001L for the treatment of hypertension and related diseases
Status	Granted	Granted	Granted	Under review **Zone PCT** +	Under review **Zone PCT**	Under review **Zone PCT** +
Expiration date	14/01/2019	16/07/2023 *	06/08/2024 **	07/11/2031	21/12/2032 *	10/2033 *

Patents operated by Quantum Genomics provide secure protection for future drugs up to 2033 (plus potential 5 years extension)

* Potential patent protection extention for 5 years
** Data exclusivity if the patent expires before the date of market availability (10 years in France, 5 years in the USA)

A model of outsourcing using best partners in each area for excellence and reactivity

Optimized cash management

Data in K€ - audited	FY 2014	FY 2013	FY 2012
Net income corrected for non-cash effects	(2,034)	(1,532)	(831)
Change in net working capital	(757)	545	217
Fixed assets	(350)	(113)	(61)
FREE CASH FLOW	**(3,141)**	**(1,100)**	**(675)**
Capital increase	3,699	831	336
Borrowings and shareholders' loans	3,307	1,043	419
Debt repayment	(1,042)	(419)	0
Other elements (mainly Bpifrance loans)	162	(75)	(143)
FINANCINGS	**8,210**	**1,380**	**610**
Change in cash	2,984	280	(65)
CASH (END OF PERIOD)	3,318	334	54

Cash from inception
December 23, 2005 to December 31, 2014

€ 13.6 million
Operating expenses (primarily R&D)

€ 13.6 million
Equity/shareholders financing

€ 1.7 million
Subsidies from Bpifrance (Public Innovation Bank) and ANR (National Research Agency)

€ 1.6 million
Research Tax Credits (RTC)

3.0 M€ loan from the shareholder Téthys was converted into capital during the public equity offering of February 2015

A successful public equity offering in February 2015

Capital increase
12.9 M€
to cover the following
4 R&D programs

QGC001

- Completion of phase IIa for hypertension
- Implementation of studies necessary to prepare the approval file for phase IIb (pivotal trial)

QGC101

- Finalisation of the preclinical studies and then move directly to phase II

QGC006

QGC011

- Progress of preclinical studies on combinations QGC011 with other antihypertensive drugs and the "best-in-class" product QGC006 (with superiority in the same therapeutic category)

Shareholding& stock exchange information

Current capital breakdown

(6,859,962 shares)



5 family offices:	
Alix AM	14.7%
Téthys	11.6%
Grand Allied	11.5%
Delore	4.1%
Ador	2.8%

Stock market data

- Listed on Marché Libre (Euronext) since July 2009
- Listed on Alternext Paris since April 10, 2014
- ISIN : FR0010783837
- Ticker code : ALQGC
- Market capitalisation: 45.8 M€ as of April 21, 2015

ALQGC LISTED ALTERNEXT

ELIGIBLE PEA PME

ENTREPISE INNOVANTE bpifrance

Potential dilution

- Up to 1,161,038 new shares could be issued if all existing common share purchase warrants were to be exercised, which represents 14.5% potential dilution
- Company policy is to issue warrants after each capital increase such that potential dilution never exceeds 15% at any time

Quantum Genomics

4 A strategy focused on rapid value creation

Blockbuster patent expiration creates opportunity

Top-selling antihypertensive drugs

Blockbuster (I.N.N.)	Company	Main Patent expiration date
Diovan (valsartan)	NOVARTIS	Sept. 2012
Micardis (telmisartan)	Boehringer Ingelheim / Bayer HealthCare Pharmaceuticals	Jan. 2014
Benicar, Olmetec (olmesartan)	Daiichi-Sankyo	Oct. 2016
Avapro, Aprovel (irbesartan)	SANOFI / Bristol-Myers Squibb	Mar. 2014
Blopress (candesartan)	Takeda / AstraZeneca	Jun. 2012

- **Antihypertensive drugs account for 5 of 10 top-selling cardiovascular products, each with annual sales >$1 billion**
- **Increasing generic threat creates significant need for innovative antihypertensive therapeutics candidates**
- **Pipelines lack innovation; majority of late stage programs focused on combination therapies using existing drugs**

Quantum Genomics aims to sign a partnership agreement with a Pharmaceutical Company while QGC001 is in phase II :

Goal

Building an alliance with a pharmaceutical company to develop the BAPAI platform

Upfront/ Milestones

Financing clinical and regulatory trials starting from the signature of the license

Royalties

The partner will be in charge of marketing and sales activities

Starting sales ASAP after New Drug Approval

Quantum Genomics will receive royalties on sales

Representative Transactions

Acquirer	Developer	Indication	Status	Terms
SERVIER	xention creating new medicines	Cardiovascular	Phase I	Upfront payment + up to **€ 120 million** licence fees and milestone payments; Servier to continue development of XEN-D0103; Owns commercial rights ex US and Japan
NOVARTIS	Speedel	Hypertension	Phase II	**Acquisition (90,3% of shares) : $ 882.3 million**

Sources: companies press release

5 reasons to become a shareholder

QGC001: lead asset with blockbuster potential

- Currently in phase II for hypertension
- Leading anti-hypertensive drugs facing patent expiration

Unique approach in a large market

- $40 Billion in annual anti-hypertensive drug sales worldwide
- >50% of hypertension patients lack adequate treatment

Robust pipeline of new drugs

- 3 compounds in development for hypertension and 1 for congestive heart failure

BAPAI: novel therapeutic class for hypertension

- Targets new pharmacological pathway in brain

Strong IP Portfolio

- Exploitation of exclusive worldwide rights to fundamental BAPAI patents
- Multiple patent applications pending

Quantum Genomics

Appendices

Annex 1 – Design of the Phase I Clinical Studies



Inclusion criteria:
- Caucasian male healthy subjects of 18 to 45 years of age
- Body mass index ≤ 27 kg / m2
- Non-smoker or less than 5 cigarettes per day

Annex 2 – Existing antihypertensive drugs



Sources : IMS Health

Annex 3 – Simplified income statements and balance-sheet

Audited data in € French GAAP	2014	2013
Revenue	12,000	17,400
Purchases and external expense	1,102,708	1,087,662
Personnel expenses	1,302,840	764,719
OPERATING RESULT	**(2,417,548)**	**(1,902,545)**
EARNINGS BEFORE TAX	**(2,536,935)**	**(1,914,382)**
EXTRAORDINARY INCOME	**(4,889)**	**(1,028)**
Research Tax Credit (RTC)	334,953	373,980
NET INCOME	(2,206,871)	(1,541,430)

Audited data in € French GAAP	12/31/2014
Fixed assets	623,502
Current receivables	644,613
Cash	3,318,033
Prepaid expenses	166,462
TOTAL ASSETS	**4,752,610**
Shareholders equity	(129,793)
Other equity (conditional advance)	727,500
Provisions	-
Financial debt	3,307,707
Other liabilities	847,196
TOTAL EQUITY AND LIABILITIES	4,752,610

Annex 4 – Pharmaceutical companies looking for partners

Top dealmakers 2012 (number of deals)

Partnering remains of huge strategic importance to pharmaceutical companies, as R&D productivity declines, blockbuster drug revenues fall off the patent cliff and growth in the major markets stalls



- **Approximately 600 R&D deals/ year WW**
- **800 to 1 000 Licensing deals/year WW**
- **300 to 400 M&A/ year WW**

Source : Source : PharmaDeals® V4 - Top dealmakers of 2012

Quantum Genomics

QUANTUM GENOMICS SA
Tour Montparnasse
33 avenue du Maine
75015 PARIS
FRANCE
T : + 33 (0)1.85.34.77.70
lionel.segard@quantum-genomics.com

ALQGC
LISTED
ALTERNEXT